Omaxe Financials
| OMAXE Stock | 99.40 3.22 3.14% |
Operating Margin (0.46) | Profit Margin (0.25) | Return On Equity (0.58) |
Omaxe | Select Account or Indicator |
Understanding current and past Omaxe Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Omaxe's financial statements are interrelated, with each one affecting the others. For example, an increase in Omaxe's assets may result in an increase in income on the income statement.
Omaxe Stock Summary
Omaxe competes with Vishnu Chemicals, Hindware Home, Sukhjit Starch, Zuari Agro, and Mangalore Chemicals. Omaxe is entity of India. It is traded as Stock on NSE exchange.Specialization | Real Estate, Real Estate Management & Development |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE800H01010 |
| Business Address | Omaxe House, New |
| Sector | Real Estate Management & Development |
| Industry | Real Estate |
| Benchmark | Dow Jones Industrial |
| Website | www.omaxe.com |
| Phone | 91 11 4189 6680 |
You should never invest in Omaxe without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Omaxe Stock, because this is throwing your money away. Analyzing the key information contained in Omaxe's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Omaxe Key Financial Ratios
Omaxe's financial ratios allow both analysts and investors to convert raw data from Omaxe's financial statements into concise, actionable information that can be used to evaluate the performance of Omaxe over time and compare it to other companies across industries.| Revenue | 16.14 B | ||||
| Gross Profit | (682.8 M) | ||||
| EBITDA | (3.48 B) | ||||
| Net Income | (4.03 B) | ||||
| Cash And Equivalents | 62.9 M |
Omaxe Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 105.5B | 110.4B | 119.2B | 135.6B | 138.2B | 88.8B | |
| Other Current Liab | 32.5M | 28.8M | 71.5B | 99.5B | 107.8B | 113.2B | |
| Net Debt | 15.8B | 13.5B | 9.1B | 9.2B | 2.6B | 2.4B | |
| Accounts Payable | 12.2B | 10.8B | 10.0B | 11.9B | 11.4B | 9.7B | |
| Cash | 335.6M | 1.1B | 1.3B | 1.9B | 5.4B | 5.7B | |
| Net Receivables | 6.2B | 8.2B | 8.2B | 5.9B | 3.6B | 3.4B | |
| Inventory | 82.4B | 85.9B | 92.7B | 104.3B | 105.1B | 57.3B | |
| Other Current Assets | 11.0B | 3.7B | 5.2B | 15.8B | 10.5B | 8.2B | |
| Total Liab | 88.9B | 96.2B | 106.6B | 126.5B | 133.3B | 70.4B | |
| Total Current Assets | 93.7B | 98.9B | 107.3B | 123.0B | 124.6B | 81.0B | |
| Retained Earnings | 3.4B | 1.0B | (591.8M) | (114.6M) | (8.1B) | (7.7B) | |
| Short Term Debt | 6.2B | 5.8B | 5.2B | 3.3B | 2.7B | 4.5B | |
| Other Liab | 2.4B | 2.4B | 3.4B | 4.0B | 3.6B | 3.0B | |
| Net Tangible Assets | 15.7B | 13.5B | 11.9B | 8.5B | 7.6B | 13.2B | |
| Other Assets | 4.2B | 4.7B | 5.4B | 5.2B | 138.2B | 145.1B | |
| Long Term Debt | 9.2B | 8.7B | 5.2B | 7.6B | 8.8B | 8.2B | |
| Short Long Term Debt | 5.7B | 1.6B | 4.9B | 2.6B | 2.3B | 4.5B | |
| Long Term Debt Total | 10.5B | 9.5B | 6.0B | 7.8B | 8.9B | 9.2B | |
| Cash And Equivalents | 1.5M | 2.1M | 2M | 62.9M | 72.3M | 76.0M | |
| Net Invested Capital | 30.7B | 24.3B | 22.5B | 19.2B | 17.3B | 22.9B |
Omaxe Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 1.1B | 1.4B | 1.0B | 1.1B | 1.3B | 1.0B | |
| Total Revenue | 11.2B | 4.8B | 6.2B | 7.7B | 16.1B | 11.0B | |
| Gross Profit | 3.4B | 21.9M | 601.7M | (929.6M) | (1.8B) | (1.7B) | |
| Operating Income | 1.2B | (1.7B) | (934.3M) | (3.6B) | (4.0B) | (3.8B) | |
| Ebit | (7.6B) | (7.4B) | (7.6B) | (14.0B) | (4.0B) | (4.2B) | |
| Ebitda | 2.3B | (971.6M) | (464.6M) | (2.8B) | (3.5B) | (3.3B) | |
| Income Before Tax | 442.6M | (3.0B) | (1.9B) | (4.6B) | (5.1B) | (4.8B) | |
| Net Income | (972.2M) | (2.4B) | (1.6B) | (3.5B) | (4.0B) | (3.8B) | |
| Income Tax Expense | 1.4B | (694.3M) | (327.3M) | (1.1B) | (1.0B) | (961.0M) | |
| Cost Of Revenue | 7.9B | 4.7B | 5.6B | 8.7B | 17.9B | 18.8B | |
| Minority Interest | 172.5M | 171.6M | 20.8M | 31.7M | 33.1M | 31.4M | |
| Tax Provision | 184.9M | (694.3M) | (327.3M) | (1.1B) | (1.0B) | (961.0M) | |
| Interest Income | 1.1B | 1.6B | 1.2B | 1.1B | 1.0B | 964.4M | |
| Net Interest Income | (842.6M) | (1.6B) | (1.2B) | (1.1B) | (1.3B) | (1.4B) |
Omaxe Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 1.8B | (3.6B) | (6.7B) | (11.6B) | 3.2B | 3.4B | |
| Change In Cash | (388.8M) | 721.1M | 208.8M | 651.9M | (13.9M) | (13.2M) | |
| Free Cash Flow | 7.1B | 5.6B | 7.7B | 4.5B | 9.7B | 10.2B | |
| Depreciation | 774.5M | 673.4M | 497.4M | 681.3M | 542.6M | 299.5M | |
| Other Non Cash Items | 4.2B | 4.5B | 3.5B | 4.9B | 198.4M | 188.5M | |
| Capital Expenditures | 97.4M | 74.5M | 171.5M | 204.4M | 168.4M | 151.8M | |
| Net Income | 442.6M | (3.0B) | (1.9B) | (4.6B) | (4.0B) | (3.8B) | |
| End Period Cash Flow | 335.6M | 1.1B | 1.3B | 1.9B | 1.9B | 1.1B | |
| Dividends Paid | 39.4M | 42.9M | 32.4M | 2.8M | 300K | 2.7M | |
| Investments | 259.6M | 227.2M | 1M | (1.4B) | (640.2M) | (608.2M) | |
| Net Borrowings | (4.6B) | (2.6B) | (4.3B) | (639.7M) | (575.7M) | (604.5M) | |
| Change To Netincome | 5.6B | 3.9B | 3.2B | 3.8B | 4.4B | 4.5B |
Omaxe Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Omaxe's current stock value. Our valuation model uses many indicators to compare Omaxe value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Omaxe competition to find correlations between indicators driving Omaxe's intrinsic value. More Info.Omaxe Limited is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Omaxe by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Omaxe's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Omaxe Limited Systematic Risk
Omaxe's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Omaxe volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Omaxe Limited correlated with the market. If Beta is less than 0 Omaxe generally moves in the opposite direction as compared to the market. If Omaxe Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Omaxe Limited is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Omaxe is generally in the same direction as the market. If Beta > 1 Omaxe moves generally in the same direction as, but more than the movement of the benchmark.
Omaxe Limited Total Assets Over Time
Omaxe November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Omaxe help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Omaxe Limited. We use our internally-developed statistical techniques to arrive at the intrinsic value of Omaxe Limited based on widely used predictive technical indicators. In general, we focus on analyzing Omaxe Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Omaxe's daily price indicators and compare them against related drivers.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 9.84 | |||
| Value At Risk | (3.95) | |||
| Potential Upside | 5.0 |
Other Information on Investing in Omaxe Stock
Omaxe financial ratios help investors to determine whether Omaxe Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Omaxe with respect to the benefits of owning Omaxe security.